過氧化物酶體增殖物激活受體γ(PPARg)檢測試劑盒(酶聯(lián)免疫吸附試驗(yàn)法)
ELISA Kit for Peroxisome Proliferator Activated Receptor Gamma (PPARg)
PPAR-G; PPARG1; PPARG2; NR1C3; Glitazone Receptor; Nuclear Receptor Subfamily 1 Group C Member 3
- 編號USEA886Bo
- 物種Bos taurus; Bovine (Cattle，牛) 相同的名稱，不同的物種。
- 實(shí)驗(yàn)方法雙抗夾心
- 反應(yīng)時長3h
- 檢測范圍0.312-20ng/mL
- 靈敏度最小可檢測劑量小于等于0.133ng/mL.
- 樣本類型Serum, plasma, tissue homogenates, cell lysates, cell culture supernates and other biological fluids
- 下載 英文說明書 中文說明書
- 規(guī)格 48T96T 96T*5 96T*10 96T*100
- 價格 ¥ 1588 ¥ 2268 ¥ 10206 ¥ 19278 ¥ 158760
- 欲了解實(shí)際交易價格和更多情況，請與當(dāng)?shù)亟?jīng)銷商聯(lián)系!
-
產(chǎn)品包裝(模擬)
-
產(chǎn)品包裝(模擬)
-
實(shí)驗(yàn)結(jié)果圖
-
標(biāo)準(zhǔn)曲線圖
-
通過ISO 9001、ISO 13485質(zhì)量體系認(rèn)證
特異性
本試劑盒用于檢測過氧化物酶體增殖物激活受體γ(PPARg)，經(jīng)檢測與其它相似物質(zhì)無明顯交叉反應(yīng)。
由于受到技術(shù)及樣本來源的限制，不可能完成對所有相關(guān)或相似物質(zhì)交叉反應(yīng)檢測，因此本試劑盒有可能與未經(jīng)檢測的其它物質(zhì)有交叉反應(yīng)。
回收率
分別于定值血清及血漿樣本中加入一定量的過氧化物酶體增殖物激活受體γ(PPARg)（加標(biāo)樣品），重復(fù)測定并計(jì)算其均值，回收率為測定值與理論值的比率。
| 樣本 | 回收率范圍(%) | 平均回收率(%) |
| serum(n=5) | 80-101 | 87 |
| EDTA plasma(n=5) | 87-96 | 92 |
| heparin plasma(n=5) | 88-98 | 92 |
精密度
精密度用樣品測定值的變異系數(shù)CV表示。CV(%) = SD/mean×100
批內(nèi)差：取同批次試劑盒對低、中、高值定值樣本進(jìn)行定量檢測,每份樣本連續(xù)測定20 次，分別計(jì)算不同濃度樣本的平均值及SD值。
批間差：選取3個不同批次的試劑盒分別對低、中、高值定值樣本進(jìn)行定量測定，每個樣本使用同一試劑盒重復(fù)測定8次，分別計(jì)算不同濃度樣本的平均值及SD值。
批內(nèi)差： CV<10%
批間差： CV<12%
線性
在定值血清及血漿樣本內(nèi)加入適量的過氧化物酶體增殖物激活受體γ(PPARg)，并倍比稀釋成1:2，1:4，1:8，1:16的待測樣本，線性范圍即為稀釋后樣本中過氧化物酶體增殖物激活受體γ(PPARg)含量的測定值與理論值的比率。
| 樣本 | 1:2 | 1:4 | 1:8 | 1:16 |
| serum(n=5) | 91-104% | 80-98% | 96-104% | 92-101% |
| EDTA plasma(n=5) | 98-105% | 87-94% | 84-104% | 80-96% |
| heparin plasma(n=5) | 85-93% | 78-104% | 92-104% | 78-95% |
穩(wěn)定性
經(jīng)測定，試劑盒在有效期內(nèi)按推薦溫度保存，其活性降低率小于5%。
為減小外部因素對試劑盒破壞前后檢測值的影響，實(shí)驗(yàn)室的環(huán)境條件需盡量保持一致，尤其是實(shí)驗(yàn)室內(nèi)溫度、濕度及溫育條件。其次由同一實(shí)驗(yàn)員來進(jìn)行操作可減少人為誤差。
實(shí)驗(yàn)流程
1. 實(shí)驗(yàn)前標(biāo)準(zhǔn)品、試劑及樣本的準(zhǔn)備；
2. 加樣（標(biāo)準(zhǔn)品及樣本）100µL，37°C孵育1小時；
3. 吸棄，加檢測溶液A100µL，37°C孵育1小時；
4. 洗板3次；
5. 加檢測溶液B100µL，37°C孵育30分鐘；
6. 洗板5次；
7. 加TMB底物90µL，37°C孵育10-20分鐘；
8. 加終止液50µL，立即450nm讀數(shù)。
實(shí)驗(yàn)原理
將過氧化物酶體增殖物激活受體γ(PPARg)抗體包被于96孔微孔板中，制成固相載體，向微孔中分別加入標(biāo)準(zhǔn)品或標(biāo)本，其中的過氧化物酶體增殖物激活受體γ(PPARg)與連接于固相載體上的抗體結(jié)合，然后加入生物素化的過氧化物酶體增殖物激活受體γ(PPARg)抗體，將未結(jié)合的生物素化抗體洗凈后，加入HRP標(biāo)記的親和素，再次徹底洗滌后加入TMB底物顯色。TMB在過氧化物酶的催化下轉(zhuǎn)化成藍(lán)色，并在酸的作用下轉(zhuǎn)化成最終的黃色。顏色的深淺和樣品中的過氧化物酶體增殖物激活受體γ(PPARg)呈正相關(guān)。用酶標(biāo)儀在450nm波長下測定吸光度(O.D.值)，計(jì)算樣品濃度。
增值服務(wù)
相關(guān)產(chǎn)品
| 編號 | 適用物種：Bos taurus; Bovine (Cattle，牛) | 應(yīng)用(僅供研究使用，不用于臨床診斷！) |
| URPA886Bo01 | 過氧化物酶體增殖物激活受體γ(PPARg)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| UPAA886Bo01 | 過氧化物酶體增殖物激活受體γ(PPARg)多克隆抗體 | WB; IHC; ICC; IP. |
| UMAA886Bo21 | 過氧化物酶體增殖物激活受體γ(PPARg)單克隆抗體 | WB; IHC; ICC; IP. |
| USEA886Bo | 過氧化物酶體增殖物激活受體γ(PPARg)檢測試劑盒(酶聯(lián)免疫吸附試驗(yàn)法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
| ULMA886Bo | 過氧化物酶體增殖物激活受體γ(PPARg)等多因子檢測試劑盒(流式熒光發(fā)光法) | FLIA Kit for Antigen Detection. |
參考文獻(xiàn)
| 雜志 | 參考文獻(xiàn) |
| Neuroscience Letters | Elevated levels of PPAR-gamma in the cerebrospinal fluid of patients with multiple sclerosis [Pubmed: 24021801] |
| J Cell Biochem. | Nonivamide enhances miRNA let‐7d expression and decreases adipogenesis PPARγ expression in 3T3‐L1 cells [Pubmed:25704235] |
| Osteoarthritis Cartilage | Establishment of a rabbit model to study the influence of advanced glycation end products accumulation on osteoarthritis and the protective effect of pioglitazone [PubMed: 26321377] |
| J Clin Diagn Res. | Evaluation of Protein Kinase Cβ and PPARγ Activity in Diabetic Rats Supplemented with Momordica charantia [pmc:PMC4866090] |
| Journal of Clinical&Diagnostic Research | Evaluation?of?Protein?Kinase?Cβ and PPARγ?Activity?in?Diabetic?RatsSupplemented?with?Momordica?charantia. [pubmed:27190792] |
| Osteoarthritis?and?Cartilage | Establishment?of a?rabbit?model?to?study?the?influence?of?advanced?glycation?end?productsaccumulation?on?osteoarthritis?and the?protective?effect?of pioglitazone. [pubmed:26321377] |
| Neuroscience Letters | Unlike PPARgamma, neither other PPARs nor PGC-1alpha is elevated in the cerebrospinal fluid of patients with multiple sclerosis [pubmed:28483651] |
| European?Journal?of?Immunology | Engulfment of Hb‐activated platelets differentiates monocytes into pro‐inflammatory macrophages in PNH patients [Pubmed:29677388] |
| Histochemistry and?Cell Biology | Simpson–Golabi–Behmel syndrome human adipocytes reveal a changing phenotype throughout differentiation [Pubmed:29574488] |
| molecular and cellular biochemistry | Maternal omega-3 fatty acids and vitamin E improve placental angiogenesis in late-onset but not early-onset preeclampsia [Pubmed: 31420792] |
| Nutrients.? | Hyperglycemia Changes Expression of Key Adipogenesis Markers (C/EBPα and PPAR?) and Morphology of Differentiating Human Visceral Adipocytes [Pubmed: 31398873] |
| journal of biochemical and molecular toxicology | Indomethacin and juglone inhibit inflammatory molecules to induce apoptosis in colon cancer cells [Pubmed: 31916655] |
| J Cosmet Dermatol | In?\vitro effect of pine bark extract on melanin synthesis, tyrosinase activity, production of endothelin?\1 and PPAR in cultured melanocytes exposed to Ultraviolet??- [33960120] |
| American Chemical Society | TRPA1 Agonist Cinnamaldehyde Decreases Adipogenesis in 3T3-L1 Cells More Potently than the Non-agonist Structural Analog Cinnamyl Isobutyrate [33403292] |
| PLoS One | Quantitative real-time measurement of endothelin-1-induced contraction in single non-activated hepatic stellate cells [34343209] |
| Prostaglandins Leukot Essent Fatty Acids | Maternal Vitamin D Deficiency Reduces Docosahexaenoic Acid, Placental Growth Factor and Peroxisome Proliferator Activated Receptor Gamma levels in the Pup?… [34768025] |
| Food and Chemical Toxicology | Melatonin attenuates cisplatin-induced acute kidney injury in mice: Involvement of PPARα and fatty acid oxidation [Pubmed:35367536] |
